Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q3 2020 Earnings Presentation
10 slides from Harmony Biosciences's earnings presentation, Nov 12, 2020
Slide 1: Q3 2020 Financial and Business Update
Harmony Biosciences Q3 2020 Financial and Business Update November 12, 2020 Exhibit 99.2
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc
Slide 3: Harmony's Strategy for Growth
Harmony’s Strategy for Growth Optimize WAKIX® Commercial Launch Expand Clinical Utility of WAKIX® Acquire New Assets
Slide 4: WAKIX Net Product Revenue
WAKIX net product revenue ($m) WAKIX® Net Product Revenue Q3 Net Product Revenue of $45.6M, 20% Increase over Q2 2020 Continued WAKIX growth in Q3 2020 vs. Q2 2020 20% increase in net revenue 22% growth in average number of patients Continued strength in demand, patient growth
Slide 5: Q3 2020 WAKIX Launch Performance Metrics
Q3 2020 WAKIX® Launch Performance Metrics Average Number of Patients on WAKIX 2,200 ~80% >2,000 Unique HCP Prescribers Since Launch (25% of Narcolepsy HCP Prescribers) Targeted Account Lives Being Covered Positively (~182M Lives)
Slide 6: Core Attributes of WAKIX Product Profile Align with Existing Unmet Needs in Narcolepsy
Core Attributes of WAKIX® Product Profile Align with Existing Unmet Needs in Narcolepsy Top Unmet Needs in Narcolepsy (cited by patients and HCPs) WAKIX (pitolisant)* Need for non-scheduled treatment options (low/no abuse potential) First and only FDA approved non-scheduled treatment option for narc
Slide 7: Development Pipeline for Pitolisant
Development Pipeline for Pitolisant
Slide 8: Current LCM Programs for Pitolisant: Scientific Rationale
Current LCM Programs for Pitolisant: Scientific Rationale Prader-Willi Syndrome Myotonic Dystrophy Rare, genetic multi-system disease characterized by hypothalamic dysfunction; decreased hypocretin levels in some patients1,2 ~15-20,000 patients in US and more than 50% have EDS due to sleep-wake stat
Slide 9: Q3 2020 Selected Financial Results
Q3 2020 Selected Financial Results Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Net Product Revenues $45.6 $103.5 Cost of Products Sales 7.9 17.8 Gross profit 37.7 85.6 Total Operating Expenses $27.3 $29.8 $76.4 $112.2 R&D Expense 4.2 4.3 11.8 62.31 S&M Expens
Slide 10: Thank You
HARMONY BIOSCIENCES Thank You November 12, 2020
Harmony Biosciences Holdings — Q3 2020 Earnings Presentation on 6ix